Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rebecca Thrun

Internal Medicine Tulsa, OK Doctor of Osteopathy

NPI 1891131223 CMS profile 1386097

6600 S Yale Ave Ste 900, Tulsa, OK 74136

Open in the dashboard

General payments

$3,673

211 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rebecca Thrun of Tulsa, OK is reported in the CMS Open Payments database as having received $3,673 across 211 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $485 18
2024 General $529 22
2023 General $436 33
2022 General $231 14
2021 General $161 11
2020 General $251 17
2019 General $1,580 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rebecca Thrun
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Rebecca Thrun were reported at $485. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Rebecca Thrun Internal Medicine median Middle half National median
2019 $1,580 $159 $48–$570 $163
2020 $251 $119 $33–$402 $114
2021 $161 $135 $37–$521 $132
2022 $231 $141 $42–$496 $149
2023 $436 $149 $45–$519 $160
2024 $529 $154 $47–$537 $164
2025 $485 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $525 35 payments
  2. Novartis Pharmaceuticals Corporation $343 13 payments
  3. Pfizer Inc. $310 17 payments
  4. Abbott Laboratories $235 16 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $213 8 payments
  6. AstraZeneca Pharmaceuticals LP $213 13 payments
  7. Merck Sharp & Dohme Corporation $166 17 payments
  8. GlaxoSmithKline, LLC. $162 12 payments
  9. Teleflex LLC $149 1 payment
  10. Insulet Corporation $139 1 payment
  11. Other $1,219 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,664 210 payments
  2. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. QULIPTA $360 22 payments
  2. ENTRESTO $343 13 payments
  3. UBRELVY $301 15 payments
  4. EUCRISA $174 8 payments
  5. JARDIANCE $165 6 payments
  6. UROLIFT $149 1 payment
  7. Omnipod $139 1 payment
  8. TRELEGY ELLIPTA $124 9 payments
  9. COLOGUARD $116 10 payments
  10. JANUVIA $114 13 payments
  11. Other $2,674 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 104 drugs

Part D claims

4,971

Median for Internal Medicine: 777

Drug cost

$476,633

Median for Internal Medicine: $73,373

Branded share of claims

17.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 63 $79,873
Ozempic Semaglutide Brand 38 $64,008
Trulicity Dulaglutide Brand 36 $62,621
Jardiance Empagliflozin Brand 24 $31,550
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 25 $30,356
Eliquis Apixaban Brand 32 $24,671
Xarelto Rivaroxaban Brand 19 $20,827
Farxiga Dapagliflozin Propanediol Brand 12 $17,818
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 27 $17,776
Myrbetriq Mirabegron Brand 21 $13,382

The 10 drugs with the highest cost, of 104 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$100,900

Of which drugs: $9,382

Medicare patients

283

Average age 74

Services billed

1,824

211 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 40%
Osteoporosis 36%
Ischemic heart disease 29%
Depression 28%
Chronic kidney disease 26%
Cancer 19%
Diabetes 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 58 58 $4,746
Pcv20 vaccine im 90677 Office 14 14 $4,062

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $59
$59 — —
QULIPTA
  • AbbVie, Inc. $59
$59 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $35
$35 — —
Auvelity
  • Axsome Therapeutics, Inc. $31
$31 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $21
$21 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

211 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record